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Introduction: Cell-free plasma hemoglobin is associated with poor outcome in patients with sepsis. Extracellular
hemoglobin and secondarily released heme amplify inflammation in the presence of microbial TLR ligands and/or
endogenous mediators. Hemopexin, a plasma protein that binds heme with extraordinary affinity, blocks these
effects and has been proposed as a possible treatment approach to decrease inflammation in critically ill patients.
Methods: We studied mouse models of endotoxemia, burn wound infections and peritonitis in order to assess if a
repletion strategy for hemopexin might be reasonable. We also measured hemopexin in small numbers of three
patient populations that might be logical groups for hemopexin therapy: patients with sepsis and ARDS, patients
with severe burns, and premature infants.
Results: Despite severe disease, mean plasma hemopexin levels were increased above baseline in each murine
model. However, plasma hemopexin levels were decreased or markedly decreased in many patients in each of the
three patient populations.
Conclusions: Potentially different behavior of hemopexin in mice and humans may be important to consider when
utilizing murine models to represent acute human inflammatory diseases in which heme plays a role. The findings raise
the possibility that decreased hemopexin could result in insufficiently neutralized or cleared heme in some patients
with ARDS, burns, or in premature infants who might be candidates to benefit from hemopexin administration.Introduction
Red blood cells (RBCs) are disrupted in multiple clinical
settings, releasing hemoglobin and its breakdown
product heme into tissues or the intravascular space.
Free heme is toxic and may cause oxidizing injury and
minor inflammation except in unusual circumstances [1,2].
In the presence of infection, extracellular hemoglobin and
heme amplify inflammation by synergizing with microbial
Toll-like receptor (TLR) agonists and non-microbial
endogenous ligands, such as high-mobility group box 1
protein (HMGB1), to induce high levels of proinflammatory
cytokines including tumor necrosis factor (TNF) and
interleukin 6 (IL-6) [3-5].
Free hemoglobin is eliminated by binding to plasma
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unless otherwise stated.monocytic lineage via receptor CD163 [6]. Free heme
binds to a 60 kD plasma glycoprotein hemopexin
(Hx) that has extraordinarily high affinity (Kd <1 pM)
for heme, and then is transported into hepatocytes
and macrophages via receptor CD91 [7]. Several lines
of evidence have suggested that Hx could be beneficial in
settings where infection and free heme coexist. First, Hx
decreases the synergistic production of TNF and IL-6
from macrophages exposed to heme or hemoglobin
together with lipopolysaccharide (LPS), Escherichia coli,
Staphylococcus aureus or HMGB1 [3,5,8]. Second, Hx has
been protective in mouse models of sepsis [8] and sickle
cell anemia [9]. Third, elevated cell-free plasma hemoglobin
[10,11] or decreased plasma Hx [8] is associated with
increased mortality in sepsis. These studies support the
concept that free hemoglobin and heme may drive or
amplify tissue inflammation that might be suppressed by
Hx, either through direct sequestering of free heme, or
possibly indirectly through activation of heme oxygenase-1
(HO-1), inducing the production of anti-inflammatory COs is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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decreased in settings of hemolysis such as thalassemia and
sickle cell disease [9,14]. However, much less is known
about levels of Hx in inflammation or infection.
We measured plasma Hx concentrations in three diverse
populations: patients with sepsis and acute respiratory
distress syndrome (ARDS), patients with burns, and
premature infants. These studies support the notion
that there are some clinical settings in humans in
which Hx is substantially depleted, paving the way for
further studies in humans to investigate the potential
therapeutic use of Hx to treat heme-amplified inflammation
in infectious diseases. We also studied Hx in three
mouse models: endotoxemia, burn wound infection,
and peritonitis with fibrin and a blood clot. We found
that mean Hx levels remained above baseline in each
of the mouse models, suggesting that the study of
heme-related pathophysiology in mouse models of infection
may not reflect the human condition.
Methods
Materials
LPS from E. coli O55:B5 was purchased from List
Biologicals (Campbell, CA, USA). E. coli O4:K54:H5
(CP9) was a gift from Tom Russo (University of Buffalo,
Buffalo, NY, USA). Mouse hemoglobin was purified as
described previously [3]. Fibrin and thrombin were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Animal models
The animal studies were approved by the Massachusetts
General Hospital (MGH) Institutional Animal Care and
Use Committee. Six- to eight-week-old female C57BL/6
mice (Charles River Laboratories, Wilmington, MA, USA)
were used in the studies.
Endotoxemia
Mice were injected via tail vein with 40 μg of LPS
(2 mg/kg) or 4 mg of purified mouse hemoglobin or
both in a volume of 200 μl, and were bled via tail vein at
24 hours before, 1 and 4 hours after the injection. Cardiac
puncture was performed 24 hours after the injection.
Burn mouse model of gram-negative sepsis
The mouse burn wound infection model was performed
as described previously [15], followed immediately by
subcutaneous injection of E. coli O4 at log phase into
the burned area as described. Blood was collected from
the tail vein at different times, except the terminal bleed,
which was done by cardiac puncture. Mice were given
400 μl saline intraperitoneally after tail vein bleeding. In
separate experiments, we verified that baseline mouse
Hx levels in blood obtained from a group of mice
that underwent cardiac puncture were not statisticallydifferent than levels from a group of mice that had blood
drawn from the tail vein (see Figure S1 in Additional file 1).
Peritonitis model of gram-negative sepsis
This model of sepsis due to peritonitis was adapted from
Ahrenholz and Simmons as described previously [15,16].
Mice were implanted with a fibrin clot with or without
E. coli O4 as desired or with 250 μl of blood in the
peritoneum. All mice were administered 0.5 ml of saline
intraperitoneally immediately following surgery. Some
mice were given intramuscular injection of ceftriaxone
(1 mg/mouse) 2 hours after the surgery. Blood was
obtained by cardiac puncture 24 hours after surgery
for determination of bacteremia (by culture of dilutions
on Luria Broth agar plates) and for measuring Hx
and cytokines in the plasma.
Human studies
All human studies were approved by the Partners Human
Research Committee covering both Brigham and Women’s
Hospital (BWH) and MGH. Blood samples were collected
to make plasma by using BD vacutainer blood collection
tubes with sodium heparin (Becton Dickinson and Com-
pany, Franklin Lakes, NJ, USA). All blood donors or pa-
tients except infants were aged between 18 and 40 years.
All adult patients had a pre-existing central venous catheter
for blood collection. Exclusion criteria included inability
to obtain informed consent, pregnancy, and concurrent
glucocorticoid or immunosuppressive treatment.
Control volunteer blood donors
Nine female and ten male healthy donors were recruited
through the MGH and Partners clinical studies website.
Additional inclusion criteria included a normal physical
examination, a normal total hemoglobin concentration
(>12.5 g/dl), and normal values of blood tests. Exclusion cri-
teria included psychiatric disturbances, systemic disease, ac-
tive smoking or less than 1 year of smoking cessation,
alcohol use, any use of medications during the past 7 days,
antibiotic use within 48 hours, and any type of cancer.
Adult patients with severe sepsis and ARDS
Blood samples were collected within 48 hours of diagnosis
of sepsis and ARDS in 10 patients recruited from the MGH
Surgical Intensive Care Unit. Additional inclusion criteria
included clinical and laboratory diagnosis of the consensus
definition of severe sepsis, ventilator dependence, and the
diagnosis of ARDS made by the clinical team. Seven of the
ten patients had a source of sepsis in the abdomen and one
of the ten had had surgery.
Adult patients with severe burns
Blood samples were collected from five patients with
severe burns (greater than 20% total body surface area) in
Figure 1 Plasma hemopexin concentrations in mouse endotoxemia
model. C57BL/6 mice were injected intravenously with (A) hemoglobin
(Hb) 4 mg/mouse (n = 6), or (B) lipopolysaccharide (LPS) (2 mg/kg)
(n = 8) or (C) both (n = 8) via tail vein. Mouse hemopexin (mHx)
concentrations were measured 24 h before or 1 h, 4 h, or 24 h
after the intravenous injection. Data are analyzed by repeated
measures one-way analysis of variance (ANOVA). Horizontal lines
represent means. ***P <0.001, ****P <0.0001, −24 h vs. +24 h.
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(day 1) and days 3, 5 and then each week for 3 more
weeks after admission to the hospital.
Premature infants at various gestational ages
Cord blood was collected immediately after the birth
from 149 infants born at 23 to 25, 26 to 28, 29 to 31, 32
to 34, 35 to 37, and greater than 38 weeks that were
enrolled in a study of cord blood vitamin D levels at
BWH, Boston, MA, USA.
Assays for hemopexin, heme, and cytokines
Mouse and human plasma samples were saved at −80°C
and assessed for Hx concentrations using enzyme-linked
immunosorbent assay (ELISA) kits from GenWay Biotech
Inc. (San Diego, CA, USA), heme concentrations by heme
assay kits from BioVision Inc. (Milpitas, CA, USA), and
TNF or IL-6 levels by ELISA kits from R&D Systems
(Minneapolis, MN, USA).
Statistics
Data were analyzed by GraphPad Prism 6 (GraphPad
Software, La Jolla, CA, USA). P <0.05 was considered to
be statistically significant. D’Agostino-Pearson omnibus
normality test was performed to assess the normality of
the samples. Two-tailed unpaired t test was performed
to compare two independent groups of samples of ARDS
patients. To compare more than two samples, we per-
formed analysis of repeated measures or ordinary one-way
analysis of variance (ANOVA) for Gaussian distributed
samples and Kruskal-Wallis tests for non-Gaussian
distributed samples, respectively. To do pairwise compari-
sons, Donnett’s and Tukey’s tests were used for Gaussian
and Dunn’s tests were used for non-Gaussian distributed
samples. Pearson correlation analysis was performed for
correlation studies of bacteremia with plasma IL-6 or Hx
concentrations in the mouse peritonitis model.
Results
Hx in mouse models
Endotoxemia
Mice were injected with hemoglobin, LPS, or a mixture
of both. Hemoglobin alone did not induce TNF. LPS
induced the production of TNF, which was significantly
enhanced by injection with LPS (data not shown), as has
been previously described [17]. Hemoglobin alone did
not have an effect on the levels of Hx in the plasma, but
LPS with or without hemoglobin significantly increased
Hx concentrations (Figure 1).
Burn mouse model with gram-negative sepsis
We studied Hx in a mouse burn wound infection model
as described previously [15,16]. Plasma Hx concentrations
increased by day 1 and became significantly increased ondays 5, 7 and 9 after the burn and infection with E. coli
O4 106 cfu/mouse (Figure 2). In mice with severe
infections (E. coli O4 107 cfu/mouse injected), Hx
was increased by day 1 and remained above baseline
despite high bacteremia and high levels of IL-6. Eighty
percent of these mice died. Mice with the lowest Hx levels
survived the shortest time (data not shown).
Peritonitis model of gram-negative sepsis
In the peritonitis model with implantation of a peritoneal
blood clot with or without E. coli, Hx levels increased at
24 hours by two- to threefold compared with controls
Figure 2 Plasma hemopexin concentrations in mouse burn model
with infection. C57BL/6 mice (n = 6) were subjected to burn by
boiled brass bars on the dorsal surface for 30 seconds under
anesthesia, followed by a subcutaneous injection of E. coli O4
(106 cfu/mouse) into the burned area. Mouse hemopexin (mHx)
concentrations were measured 1 day before or 1, 3, 5, 7 and 9 days
after the burn. The time of the burn is considered as ‘0’ time. P <0.01
for the whole experiment analyzed by repeated measures one-way
analysis of variance (ANOVA). Donnett’s test was done for comparisons
to the control. Horizontal lines represent means. *P <0.05, − 1 day
vs. +5, or +7, or +9 days.
Figure 3 Plasma hemopexin concentrations in mouse peritonitis
model with fibrin clot. C57BL/6 mice were subjected to
intraperitoneal implantation of fibrin clots only (sham, n = 6) or with
blood clots (Bld, n = 9) or with E. coli O4 104 cfu/mouse (n = 5) or
106 cfu/mouse (n = 37, 8 mice died) or E. coli O4 106 cfu/mouse with
ceftriaxone (ceftr.) (1 mg/mouse) (n = 12) injected intramuscularly
2 hours after the laparotomy. Mouse hemopexin (mHx) concentrations
were measured in naïve mice (n = 12) or in treated mice 24 hours after
the laparotomy. Data are analyzed by one-way analysis of variance
(ANOVA) and Tukey’s test was done for pairwise comparisons. Horizontal
lines represent means. Data were from nine independent experiments.
**P <0.01; ***P <0.001; ****P <0.0001.
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from those mice with surgery plus implantation of a blood
clot with or without E. coli 104 cfu/mouse (Figure 3).
Increasing the bacterial inoculation in the blood clot
to106 cfu/mouse significantly decreased the Hx levels
compared to the clot with 104 cfu/mouse, although
even with these high bacterial inocula the median Hx
level remained above those of naïve mice. The decrease in
Hx levels was not seen if the animals were administered
ceftriaxone 2 hours after the surgery. We also found that
bacteremia was strongly and positively correlated with
IL-6 concentrations (Figure 4A). However, IL-6 levels
were negatively correlated with Hx levels (Figure 4B).
Hx in human conditions
Sepsis and ARDS
Hx concentrations varied greatly in patients with sepsis
and ARDS (Figure 5A). Two patients had very low levels
of Hx compared to the control healthy donors (Figure 5B),
and these two patients had elevated plasma heme concen-
trations (Figure 5C).
Burn patients
During the first week after admission to the burn center,
Hx concentrations in patients with severe burns were
significantly lower than levels in the control healthy
blood donors. Levels slowly increased over the next
3 weeks (Figure 6A). Hx levels decreased again in twopatients (patient 1 and 3) during episodes of sepsis
(Figure 6B).
Premature infants
Hx concentrations in the cord blood of 149 infants at
different gestational ages were much lower than in the
19 normal adult blood donors studied (shown as a mean
by the dotted horizontal line) (Figure 7). Premature infants
at different gestational ages had significantly lower Hx
levels than those in infants delivered at gestational ages
older than 38 weeks (P <0.0001).
Discussion
The findings that heme and hemoglobin synergize
with TLR agonists, bacteria and HMGB1 to amplify
inflammation and this synergy is suppressed by Hx
[3,5,8] raise the possibility of using Hx as a treatment
in settings where free heme may be present in plasma
or tissues in the presence of infection, especially in
situations in which endogenous Hx is depleted. Here
we investigated Hx concentrations in three different
groups of patients that might be logical early target
populations for clinical trials. The goal of these studies
Figure 4 Correlation of IL-6 concentrations with bacteremia or mouse hemopexin concentrations. C57BL/6 mice (n = 48) were subjected to
intraperitoneal implantation of E. coli O4 104 to 107 cfu/mouse. Cardiac puncture was performed 24 hours after the laparotomy to collect blood
for interleukin 6 (IL-6) and hemopexin measurements. Blood samples were also diluted and spread on Luria Broth agar plates and the colonies
were counted after overnight incubation at 37°C. Bacteremia was calculated and presented as cfu/ml. Pearson correlation analysis was performed.
(A) Log IL-6 (pg/ml) vs. Log E. coli (cfu/ml) (6 out of 48 mice without bacteremia were not included); (B) Log IL-6 (pg/ml) vs. mouse hemopexin
(mHx) (μg/ml). Data were from nine independent experiments.
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population to see if replenishment might be reasonable,
rather than to attempt to correlate levels with outcome,
which would require much larger studies.
We first studied patients with sepsis and ARDS.
There is evidence of increased RBC and hemoglobin
in intra-alveolar space in these patients [18], and in
mice that received intratracheal injection of LPS [19].
We found that two patients had extremely low Hx
levels (<250 μg/ml) and elevated heme levels, and the
patient with the highest heme level died. The other
patients had varied Hx levels. There have been two
prior studies of Hx in patients with sepsis of all
causes. One study found that decreased Hx correlated
with increased mortality [8]. A different study also
found that nonsurvivors had significantly lower Hx
levels than survivors [20]. These findings are consistent
with two recent studies that reported that elevated plasma
hemoglobin correlates with mortality in patients with
sepsis [10,11]. Patients in the intensive care unit who
had elevated hemoglobin but without infection did
not have increased mortality [11]. We are unaware of
prior studies of Hx in patients with ARDS. Although
our results suggest that Hx levels in patients with severe
sepsis and ARDS vary markedly, a much larger study in
this population will be needed to determine if Hx is
predictive of poor outcome in patients with ARDS.
We also studied levels of Hx in five patients with
severe burn injury. We found that Hx was depleted
in all patients on admission, and that levels in all patients
rose over a period of weeks but never above normal
values during the hospital course. Hx levels in two
patients decreased again during episodes of sepsis.
We hypothesize that heme liberated into the tissues and
blood during the acute burn injury led to temporary
consumption. This is the first report of Hx levels in
patients with burns.The third clinical setting that we evaluated was pre-
mature infants. Very low birth weight infants have
low levels of many plasma proteins, receive frequent
blood transfusions, and have greater risk of infections
than pediatric patients or adults. Premature birth is
associated with a high rate of secondary morbidities,
including acute and chronic lung disease, necrotizing
enterocolitis, retinopathy, intraventricular hemorrhage,
and intracranial white matter injury, virtually all of
which have been linked with inflammation. Furthermore,
the evolution of chronic lung disease and retinal changes
of retinopathy of prematurity (RoP) are known to be
associated with oxidant injury, and the risk of RoP
appears to be reduced by restricting blood transfusion
[21]. These and other complications associated with
hemorrhage or hemolysis are likely to be related to or
worsened by heme toxicity [22,23]. We found that all
premature infants had strikingly low levels of Hx that
gradually rose with gestational age. However, even at
gestational ages greater than 38 weeks, all infants had much
lower levels than adults. These findings are consistent with,
and extend, the prior report of Kanakoudi et al. who
reported in 1995 that Hx as measured by nephelometry
was low in premature infants [24].
Our main finding that Hx is decreased in many patients
in each setting we studied, in some cases markedly,
suggest that a subset of patients with low Hx might
benefit from Hx repletion as a therapy to decrease
inflammation in infection amplified by free heme and
hemoglobin. Most previous drugs that have been studied
in attempts to treat infection-induced inflammation by
blocking a wide variety of different aspects of the immune
system have the potential side effect of immunocompro-
mise [25]. One might expect that a repletion strategy with
a plasma protein such as Hx would have low toxicity, and
blocking excess heme seems unlikely to cause a deficit in
immune function.
Figure 5 Plasma hemopexin and heme concentrations in patients
with sepsis and acute respiratory distress syndrome (ARDS). Human
hemopexin (hHx) concentrations were measured in 10 patients with
sepsis and ARDS (1 to 10). (A) Horizontal lines represent medians.
Data were analyzed by unpaired t test. There is no significant
difference between the two groups. (B) and (C) Bars represent
hemopexin (B) and heme (C) in the plasma from individual patients
and the mean of 19 healthy donors as the control (Ctrl, dotted line).
Figure 6 Plasma hemopexin concentrations of burn patients.
Blood was drawn from 5 patients with severe burns at intervals
up to 4 weeks on different days after admission to the hospital.
Concentrations of human hemopexin (hHx) were measured in the
plasma. Samples from 19 healthy donors were used as controls
(Ctrl). (A) Data were analyzed by one-way analysis of variance
(ANOVA) and Donnett’s test was done for comparisons to the
control. Horizontal lines represent medians. *P <0.05; ***P <0.001;
****P <0.0001. (B) Bars represent the data from the individual patients
(1 to 5) at the times in the same order shown in A. Dotted line
represents the mean hHx concentration in the control sample (Ctrl).
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details of roles of heme and Hx in infection-induced
inflammation, as well as to aid in the development of
Hx preparations for human use. We investigated mouse
models for endotoxemia, burn injury, and sepsis induced
by peritonitis because we were unable to find murine
models that convincingly mimic aspects of sepsis-induced
ARDS and premature infants. Concentrations of hemo-
pexin were maintained at or above the baseline level in
most mice. Inoculation of very high numbers of bacteria
resulted in decreased levels of Hx in some mice in theperitonitis model relative to those in sham mice, but
mean levels remained above baseline. These findings
are consistent with results obtained by Larsen and et al.,
that in a mouse sepsis model of cecal ligation and
puncture (CLP), Hx concentrations were decreased
relative to mice that had sham surgery, but were not
much different than initial baseline levels [8]. The
findings are also consistent with those reported by
Spiller et al. that Hx is increased after mild CLP but
not much different from baseline after severe CLP at
later time points [26]. There is an increasing controversy
as to how well mouse models of inflammation mimic
human conditions, including in sepsis and burns, and a
recent article proposed that it may be prudent to verify
whether genes or gene products behave in a similar
manner in mice and humans [27]. Some limitations in our
study that could be factors in the appropriate comparison
of our results in mice to humans include that we studied a
Figure 7 Plasma hemopexin concentrations in infants. Hemopexin
concentrations were measured in the cord blood of 149 infants at
different gestational ages shown (23 to 25 weeks, n = 11; 26 to
28 weeks, n = 16; 29 to 31 weeks, n = 19; 32 to 34 week,
n = 19; 35 to 37 weeks, n = 42; >38 W, older than 38 weeks,
n = 42). Dotted line represents the mean human hemopexin (hHx)
concentration in healthy adult donors (800 μg/ml). Data were analyzed
by Kruskal-Wallis test and Dunn’s test was done for paired comparisons.
Horizontal lines represent means. P <0.0001, infants >38 W vs. each
group of infants at different gestational ages <38 W.
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to 8 weeks old compared to young adult patients, and that
endotoxin challenge and peritoneal infection may not
reflect sepsis causing ARDS.
Hx is an acute phase protein in several mammals,
including mice, but is less of an acute phase protein in
humans [28,29] so that inflammatory stimuli such as
infection or tissue injury lead to only slightly elevated
levels in humans. IL-6 is the main cytokine that induces
the synthesis of Hx in hepatocytes during the acute
phase response in mice [30]. We found that levels of IL-6
were positively correlated with the bacteremia as shown in
other studies [31]. However, IL-6 was negatively correlated
with Hx levels in mouse models in our studies, possibly
due to hepatic dysfunction or the increased consumption
of Hx by binding to increased free heme that outstripped
production, or both.
Conclusions
Recent reports that plasma cell-free hemoglobin is asso-
ciated with poor outcomes in sepsis [10,11], together
with data that hemoglobin and heme are synergistic with
microbial ligands to cause overactive inflammation [3],
support the hypothesis that hemoglobin or secondarily
released heme could be causative of immunopathology,
and in turn that Hx might be therapeutic [8,9]. The data
reported here that some adult patients with ARDS, most
patients with burns, and most premature infants, have
very low levels of Hx suggest the possibility that theremay be inadequate neutralization or clearance of heme
in some of these patients. Our results also suggest that it
is difficult to mimic the human Hx dynamics in mouse
inflammatory models and therefore it may be necessary
to search for a different species to model the heme axis
in human infections. A different approach might be to
perform association studies in each of the three popula-
tions studied here to show plausibility. Then, if low Hx is
associated with increased morbidity or mortality, it might
be reasonable to show that a Hx product is safe, and then
proceed directly to a treatment study using patients
selected for high extracellular heme or low Hx levels.Key messages
 Plasma hemopexin concentrations are decreased or
markedly decreased in some patients with sepsis and
acute respiratory distress syndrome, some patients
with severe burns, and most premature infants.
These results support the concept that there is a
subset of patients in each population who might
benefit from hemopexin repletion.
 Mean plasma hemopexin levels are increased above
baseline in mouse models of endotoxemia, burn
wound infection, and peritonitis-induced sepsis.
 The differing behavior of hemopexin in humans and
mice in burns, and perhaps also in other
inflammatory conditions, suggests that utilization of
mouse models to study heme-related inflammation
in humans should be done with caution.Additional file
Additional file 1: Figure S1. Mouse hemopexin concentrations are not
significantly different between plasma prepared from cardiac puncture
and from tail vein bleeding. Blood was collected by cardiac puncture
(CP, n = 15) or by tail vein bleeding (n = 32) from 6- to 8-week-old naive
C57/BL6 mice. Mouse hemopexin levels were measured in the plasma.
Data are inclusive from three pooled experiments for CP and from three
pooled experiments for tail vein bleeds and are analyzed by unpaired
t test. Horizontal lines represent medians. There is no significant difference
between the CP and tail vein groups.Abbreviations
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LPS: lipopolysaccharide; MGH: Massachusetts General Hospital; RBC: red
blood cell; RoP: retinopathy of prematurity; TLR: Toll-like receptor; TNF: tumor
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